{"id":"bax326","safety":{"commonSideEffects":[{"rate":"null","effect":"Neutropenia"},{"rate":"null","effect":"Thrombocytopenia"},{"rate":"null","effect":"Anemia"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"BAX326 works by binding to CD19 on the surface of B cells, marking them for destruction by the immune system. This mechanism is thought to be effective in treating certain types of blood cancers.","oneSentence":"BAX326 is a monoclonal antibody targeting CD19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:22:20.592Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory B-cell non-Hodgkin lymphoma"}]},"trialDetails":[{"nctId":"NCT02937831","phase":"","title":"RIXUBIS Drug Use-Result Survey (Japan)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2016-11-16","conditions":"Hemophilia B","enrollment":6},{"nctId":"NCT03565237","phase":"PHASE4","title":"RIXUBIS PMS India (RIXUBIS PMS)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2018-12-07","conditions":"Hemophilia B","enrollment":25},{"nctId":"NCT01286779","phase":"PHASE3","title":"BAX 326 (rFIX) Continuation Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-04-12","conditions":"Hemophilia B","enrollment":117},{"nctId":"NCT01174446","phase":"PHASE3","title":"Pivotal Study (Pharmacokinetics, Efficacy, Safety) of BAX 326 (rFIX) in Hemophilia B Patients","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2010-07-29","conditions":"Hemophilia B","enrollment":86},{"nctId":"NCT01488994","phase":"PHASE2, PHASE3","title":"BAX 326 Pediatric Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-12-20","conditions":"Hemophilia B","enrollment":23},{"nctId":"NCT01507896","phase":"PHASE3","title":"BAX 326 Surgery Study in Hemophilia B Patients","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-12-19","conditions":"Hemophilia B","enrollment":30},{"nctId":"NCT02922231","phase":"","title":"Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-01-06","conditions":"Hemophilia B","enrollment":57},{"nctId":"NCT01128881","phase":"PHASE4","title":"IMMUNINE Pre-Treatment Study","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2010-05-31","conditions":"Hemophilia B","enrollment":57}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["BAX 326","RIXUBIS"],"phase":"phase_2","status":"active","brandName":"BAX326","genericName":"BAX326","companyName":"Baxalta now part of Shire","companyId":"baxalta-now-part-of-shire","modality":"Biologic","firstApprovalDate":"","aiSummary":"BAX326 is a monoclonal antibody targeting CD19. Used for Relapsed or refractory B-cell non-Hodgkin lymphoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}